Prevalence of cardiovascular medication on secondary prevention after myocardial infarction in China between 1995-2015: A systematic review and meta-analysisReportar como inadecuado




Prevalence of cardiovascular medication on secondary prevention after myocardial infarction in China between 1995-2015: A systematic review and meta-analysis - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Background

Myocardial Infarction MI has become a major cause of morbidity and mortality in China, but little is known about the prevalence of guideline-recommended cardiovascular medications after MI events over the last two decades. This systematic review and meta-analysis aims to summarize cardiovascular medication use between 1995–2015 and to assess factors in associated with the trends in cardiovascular medications.

Method

A systematic search was conducted in four databases Pubmed, Embase, CENTRAL, and CNKI to obtain observational studies published between 1995 and 2015, reporting on the use of cardiovascular medications in China. Risk of bias of individual studies was appraised and selected studies were pooled for estimated prevalence of cardiovascular medication. Prevalence of cardiovascular medication use for 1995 and 2015 was estimated by random effects meta-regression model.

Results

From 13,940 identified publications, 35 studies, comprising 28,000 patients, were included. The pooled prevalence for aspirin, beta-blockers, statins, ACE-Inhibitors, ACE-Inhibitor-ARBs and nitrates was 92% 95% confidence interval CI: 0.89–0.95, 63% 95% CI: 0.57–0.69, 72% 95% CI: 0.60–0.82, 49% 95% CI: 0.41–0.57, 59% 95% CI: 0.48–0.69 and 79% 95% CI: 0.74–0.91, respectively. A significant increase in beta-blocker and statin use and a decrease of nitrate use was observed over time. The estimated prevalence of beta-blockers, statins, and nitrates was 78%, 91.1%, and 59.3% in 2015, compared to 32%, 17% and 96% in 1995, respectively.

Conclusion

Cardiovascular medication use after MI is far from optimal in Chinese patients, even though the prevalence of use increased over the period 1995–2015. With a rapidly increasing number of MI patients in China, a comprehensive strategy on secondary prevention is warranted.

Systematic review registration

PROSPERO CRD42015025246



Autor: Min Zhao , Kerstin Klipstein-Grobusch, Xin Wang, Johannes B. Reitsma, Dong Zhao, Diederick E. Grobbee, Ian Graham, Ilonca Vaartje

Fuente: http://plos.srce.hr/



DESCARGAR PDF




Documentos relacionados